Close menu

November 25th, 2021 | 10:21 CET

wallstreet:online, flatexDEGIRO, Commerzbank - Here are the winners for 2022!

  • Investments
Photo credits:

Low interest rates and high inflation are creating strong demand for equities. Even if uncertainties about upcoming interest rate increases and the fourth Corona wave prevail, the stock market lights continue to be green. Possible price setbacks represent good entry possibilities. The following three stocks offer good opportunities.

time to read: 3 minutes | Author: Carsten Mainitz

Table of contents:

    wallstreet:online - Undervalued

    At a price of around EUR 20, the shares of the largest independent operator of high-reach stock market portals in the German-speaking world offer an excellent entry level for investors with a medium-term horizon. In mid-June, EUR 26.60 had to be paid as part of a capital increase, bringing EUR 19.1 million gross into the Company's coffers for further expansion. In the past months, several insiders bought the shares, which is a strong sign of confidence. The analysts at GBC give the stock, which they rate as a "buy", a target price of EUR 37.70. That is an upside of over 80%!

    Where does the fantasy come from? The answer: transaction business. With the "neobroker" Smartbroker, which went to market at the end of 2019, the Berliners made a smart move. The central task now is to better integrate the Smartbroker's financial offerings into the stock market portals and thus leverage synergies and accelerate growth. Smartbroker differentiates itself to the broad field of neobrokers, which offer investors free stock trading, among other things, by providing low conditions and additionally a comprehensive product range.

    Smartbroker is currently in the process of completely revamping the trading front-end. In addition, the Smartbroker app will be launched next year. In our opinion, the associated investment costs will quickly pay for themselves. At the half-year point, the Group had more than 187,000 securities accounts, of which more than 142,000 were Smartbroker customers, with assets under management of EUR 6.8 billion. In the summer, an application was submitted to extend the existing KWG license. That means new revenue pots will soon emerge.

    For the current fiscal year, the management board forecast an increase in sales to around EUR 45 to 50 million and an increase in the operating result (EBITDA) to EUR 4 to 6 million. On December 7, the Berlin-based company will present itself at GBC's Munich investment conference "MKK". Perhaps the management will then elaborate on the growth plans for next year, which could pull the share out of its lethargy again. At around EUR 300 million, the stock is moderately valued.

    flatexDEGIRO - Management expects strong growth

    Europe's largest pan-European retail online broker most recently introduced commission-free trading from November 22, 2021. DEGIRO customers would now be able to trade over 5,000 US stocks directly on the leading US exchanges NASDAQ and NYSE across Europe without any commission. In addition, the offer applies to the French, Spanish, Portuguese and Italian markets.

    Management expects this to accelerate customer and company growth. The shares have been trading roughly in the range of EUR 18 to 20 over the last 2 months. The CEO and CFO of the companies have recently been rebuying more of their shares. According to analyst consensus, the title is currently trading at a 2022 P/E of 15. Most experts recommend "buy" with a price target of EUR 33.60 - an upside potential of over 70%.

    Commerzbank - New annual high marked briefly

    While business at wallstreet:online and flatexDEGIRO is humming, Commerzbank is making every effort to get back on the road to success. Central to this are the massive cost savings associated with the "Strategy 2024" strategy. Most recently, the MDAX-listed Group announced a significant step. Negotiations with the General Works Council to cut thousands of jobs had been successfully concluded, the Frankfurt-based Company announced most recently. "Now we can continue to drive forward the transformation swiftly and at full speed," commented Group CEO Manfred Knof.

    By year-end 2024, 10,000 of the most recent 39,500 full-time positions will be eliminated worldwide, but 2,500 posts will also be created. The bank is trying to carry out this reduction in a socially responsible manner. The branch network in Germany is to be reduced from 790 to 450 by the end of 2022. The share has reacted to the news with a new high for the year of just over EUR 7. However, the mark could only be held for a short time. Most analysts rate the Commerzbank share as a hold with a target price of around EUR 7.

    The upward trend in the stock markets continues. Investor trading activity also remains high. Thus, the shares of wallstreet:online and flatexDEGIRO should benefit. The analysts at GBC believe that wallstreet:online has an upside potential of over 80%. Commerzbank is also an exciting turnaround stock for 2022.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author

    Related comments:

    Commented by André Will-Laudien on May 10th, 2022 | 11:54 CEST

    GreenTech stocks are on the rise! Buy now: BASF, Meta Materials, Nordex, Siemens Energy

    • GreenTech
    • Technology
    • Investments

    The distortions on the capital markets can hardly be topped at the moment. The nickel price has risen by 300%, only to drop by 70% again. And all this in only 48 hours. There are countless examples in the current stock market environment that are historically unparalleled. In just 2 months, the Bund Future fell from 178 to 151, a loss of 16% in the 10-year Bund. In parallel, the capital market interest rate rose from minus 0.45% to a whopping plus 1.15%. So interest rates are back, inflation is spreading, and supply deficits continue to fuel the underlying stagflation scenario! One major trend should bounce back after the end of the many corrections: GreenTech! Here is a selection of interesting stocks.


    Commented by Carsten Mainitz on May 10th, 2022 | 10:39 CEST

    Zalando, Aspermont, SAP - Corona and back, the stock rebound is coming!

    • Digitization
    • Investments
    • Technology

    What would society and the economy look like without digitization? The Internet, software and smartphones have become a matter of everyday life and form the basis for communication and interaction. Corona has been an accelerator in many ways. On the other hand, pandemics and war clearly show us the limits of supposedly predictable growth with scarcity prices and supply chain disruptions. At a reduced price level, it is worth looking at "digitization stocks" that offer good opportunities.


    Commented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST

    Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus

    • Biotechnology
    • Pharma
    • Investments

    Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?